Abstract
Background:Heme Oxygenase-1 (HO-1) is a metabolic enzyme strongly involved in processes including cytoprotection, modulation of inflammatory response, anti-oxidative functions, regulation of cellular proliferation, angiogenesis, cardiovascular homeostasis, and immuno-modulation. HO-1 induction and/or activation is able to counterbalance, at least in part, oxidative stress and inflammation. For this reason, HO-1 can be regarded as an attractive target to ameliorate different stress-related pathologies. Caffeic acid phenethyl ester, a natural polyphenolic compound, behaves as HO-1 inducer and possesses a plethora of beneficial effects under oxidative stress conditions.
Objectives: A small focused series of caffeic acid phenethyl ester (Cape) analogues was designed and synthesized with the aim of obtaining more potent HO-1 inducers. Method: The capacity of these new compounds to modify the levels of HO-1 was evaluated in human mesenchymal stem cells (hMSCs) derived from bone marrow. Results and conclusion: Some of tested compounds were found to be good HO-1 inducers and 3-(3,4- dihydroxyphenyl)-(2E)-2-propenoic acid 2-(3,4-dimethoxyphenyl) ethyl ester (VP961) was the most potent. VP961 tested to measure HO-1 protein expression and HO activity in in vitro system resulted more potent than the parent compound Cape both as inducer and as direct activator of the enzyme. VP961, selected as lead compound for further characterization, showed antioxidant properties in a model of H2O2-mediated ROS production and cytoprotective effects in a model of H2O2 cells viability impairment. To the best of our knowledge, VP961 is the first known compound able to activate directly HO-1 enzyme and to induce at the same time its protein expression.Keywords: Heme oxygenase, HO-1 inducers, caffeic acid phenethyl ester, ROS, human MSCs, VP961.
Current Pharmaceutical Design
Title:Novel Caffeic Acid Phenethyl Ester (Cape) Analogues as Inducers of Heme Oxygenase-1
Volume: 23 Issue: 18
Author(s): Valeria Pittala*, Luca Vanella, Loredana Salerno, Claudia Di Giacomo, Rosaria Acquaviva, Marco Raffaele, Giuseppe Romeo, Maria N. Modica, Orazio Prezzavento and Valeria Sorrenti
Affiliation:
- Department of Drug Sciences, University of Catania, viale A. Doria 6, 95125 Catania,Italy
Keywords: Heme oxygenase, HO-1 inducers, caffeic acid phenethyl ester, ROS, human MSCs, VP961.
Abstract: Background:Heme Oxygenase-1 (HO-1) is a metabolic enzyme strongly involved in processes including cytoprotection, modulation of inflammatory response, anti-oxidative functions, regulation of cellular proliferation, angiogenesis, cardiovascular homeostasis, and immuno-modulation. HO-1 induction and/or activation is able to counterbalance, at least in part, oxidative stress and inflammation. For this reason, HO-1 can be regarded as an attractive target to ameliorate different stress-related pathologies. Caffeic acid phenethyl ester, a natural polyphenolic compound, behaves as HO-1 inducer and possesses a plethora of beneficial effects under oxidative stress conditions.
Objectives: A small focused series of caffeic acid phenethyl ester (Cape) analogues was designed and synthesized with the aim of obtaining more potent HO-1 inducers. Method: The capacity of these new compounds to modify the levels of HO-1 was evaluated in human mesenchymal stem cells (hMSCs) derived from bone marrow. Results and conclusion: Some of tested compounds were found to be good HO-1 inducers and 3-(3,4- dihydroxyphenyl)-(2E)-2-propenoic acid 2-(3,4-dimethoxyphenyl) ethyl ester (VP961) was the most potent. VP961 tested to measure HO-1 protein expression and HO activity in in vitro system resulted more potent than the parent compound Cape both as inducer and as direct activator of the enzyme. VP961, selected as lead compound for further characterization, showed antioxidant properties in a model of H2O2-mediated ROS production and cytoprotective effects in a model of H2O2 cells viability impairment. To the best of our knowledge, VP961 is the first known compound able to activate directly HO-1 enzyme and to induce at the same time its protein expression.Export Options
About this article
Cite this article as:
Pittala Valeria*, Vanella Luca, Salerno Loredana, Di Giacomo Claudia, Acquaviva Rosaria, Raffaele Marco, Romeo Giuseppe, Modica N. Maria, Prezzavento Orazio and Sorrenti Valeria, Novel Caffeic Acid Phenethyl Ester (Cape) Analogues as Inducers of Heme Oxygenase-1, Current Pharmaceutical Design 2017; 23 (18) . https://dx.doi.org/10.2174/1381612823666170210151411
DOI https://dx.doi.org/10.2174/1381612823666170210151411 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Potential of Probiotics: A Ray of Hope or Nightmare?
Applied Clinical Research, Clinical Trials and Regulatory Affairs Coronary Atherosclerotic Disease Burden: An Emerging Endpoint in Progression / Regression Studies Using Intravascular Ultrasound
Current Drug Targets - Cardiovascular & Hematological Disorders Patent Selections
Recent Patents on DNA & Gene Sequences High Sensitivity C-reactive Protein and Cardiovascular Risk Prediction
Current Pharmaceutical Analysis Endothelial Dysfunction in Sepsis
Current Vascular Pharmacology The Cardiorenal Syndrome: Pathophysiologic Crosstalk, Outcomes, and Treatment Targets
Cardiovascular & Hematological Disorders-Drug Targets Recent Progress in Development of Non-ATP Competitive Small-Molecule Inhibitors of Protein Kinases
Mini-Reviews in Medicinal Chemistry Editorial: MicroRNA-33 Inhibition: A Potential Adjunct to Statin Therapy?
Current Vascular Pharmacology Plasma Phospholipids are Associated with Mild Cognitive Impairment in Type 2 Diabetic Patients
Current Alzheimer Research Triptan-Induced Torsades de Pointes and Ventricular Fibrillation Cardiac Arrest: Case Report and Review of the Literature
Current Drug Safety Pharmacological Treatments for Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Nitric Oxide and Oral Diseases: Can We Talk About It?
Cardiovascular & Hematological Agents in Medicinal Chemistry Obstructive Sleep Apnoea Syndrome and Diabetes. Fortuitous Association or Interaction?
Current Diabetes Reviews Diterpenes: A Therapeutic Promise for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery The Neonatal Kidney: Implications for Drug Metabolism and Elimination
Current Drug Metabolism Cardioprotection by Regular Ethanol Consumption: Potential Mechanisms and Clinical Application
Current Drug Abuse Reviews Dyslipidemia Management in 2020: An Update on Diagnosis and Therapeutic Perspectives
Endocrine, Metabolic & Immune Disorders - Drug Targets Cellular Membranes and Lipid-Binding Domains as Attractive Targets for Drug Development
Current Drug Targets Mechanism Underlying the Formation of a Cluster of Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Could Additional Inhibitors of the Renin -Angiotensin System be Clinically Useful?
Current Hypertension Reviews